Nicorandil-d4 is intended for use as an internal standard for the quantification of nicorandil by GC- or LC-MS. Nicorandil is an activator of sulfonylurea receptor 2B (SUR2B) linked to ATP-sensitive potassium channel Kir6.2 (EC50 = ~10 µM) and a nitric oxide (NO) donor.1,2 It is selective for SUR2B/Kir6.2 over the SUR2A/Kir6.2 channel (EC50 = >500 µM).1 Nicorandil activates soluble guanylate cyclase in a cell-free assay and relaxes partially depolarized isolated bovine coronary artery strips (EC50 = 4.4 µM).3 It decreases mean blood pressure, coronary resistance, and heart rate, as well as increases coronary sinus outflow, in dogs when administered intravenously at a dose of 1 mg/kg.4 Nicorandil increases survival and decreases infarct size in a rabbit model of myocardial ischemia-reperfusion injury induced by left coronary artery occlusion.5 Formulations containing nicorandil have been used in the treatment of angina pectoris.
1.Shindo, T., Yamada, M., Isomoto, S., et al.SUR2 subtype (A and B)-dependent differential activation of the cloned ATP-sensitive K+ channels by pinacidil and nicorandilBr. J. Pharmacol.124(5)985-991(1998) 2.Frampton, J., Buckley, M.M., and Fitton, A.Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectorisDrugs44(4)625-655(1992) 3.Holzmann, S.Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75)J. Cardiovasc. Pharmacol.5(3)364-370(1983) 4.Taira, N., Satoh, K., Yanagisawa, T., et al.Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidoethyl nitrate (SG-75)Clin. Exp. Pharmacol. Physiol.6(3)301-316(1979) 5.Das, B.C., Sarkar, C., and Karanth, S.K.Effects of administration of nicorandil or bimakalim prior to and during ischemia or reperfusion on survival rate, ischemia/reperfusion-induced arrhythmias and infarct size in anesthetized rabbitsNaunyn-Schmiedeberg’s Arch. Pharmacol.364(5)383-396(2001)